Advertisement
Australia markets closed

  • ALL ORDS

    7,837.40
    -100.10 (-1.26%)
     

  • ASX 200

    7,575.90
    -107.10 (-1.39%)
     

  • AUD/USD

    0.6537
    +0.0013 (+0.20%)
     

  • OIL

    83.94
    +0.37 (+0.44%)
     

  • GOLD

    2,359.30
    +16.80 (+0.72%)
     

  • Bitcoin AUD

    98,368.70
    +1,213.26 (+1.25%)
     

  • CMC Crypto 200

    1,388.66
    -7.87 (-0.56%)
     

  • AUD/EUR

    0.6090
    +0.0016 (+0.27%)
     

  • AUD/NZD

    1.0979
    +0.0021 (+0.19%)
     

  • NZX 50

    11,805.09
    -141.34 (-1.18%)
     

  • NASDAQ

    17,430.50
    -96.30 (-0.55%)
     

  • FTSE

    8,106.99
    +28.13 (+0.35%)
     

  • Dow Jones

    38,085.80
    -375.12 (-0.98%)
     

  • DAX

    18,051.95
    +134.67 (+0.75%)
     

  • Hang Seng

    17,651.15
    +366.61 (+2.12%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

Repligen Corporation to Present at KeyBanc Life Science and MedTech Investor Forum

Repligen Corporation
·1-min read
Repligen Corporation
Repligen Corporation

WALTHAM, Mass., March 18, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virtually at the KeyBanc Life Science and MedTech Investor Forum being held March 22-23, 2022. Tony J. Hunt, President & Chief Executive Officer, will participate in a fireside chat on Tuesday, March 22, at 9:45 a.m. EDT.

A live webcast of the presentation will be accessible through Repligen’s Investor Relations website at www.repligen.com, and will be available for replay for a limited period of time following the event.

About Repligen Corporation
Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that increase efficiencies in the process of manufacturing biological drugs. We are inspiring advances in bioprocessing for the customers we serve; primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our corporate headquarters are located in Waltham, Massachusetts, with additional administrative and manufacturing operations worldwide. The majority of our manufacturing sites are located within the U.S. (California, Massachusetts, New Jersey and New York), and outside of the U.S. we have sites in Estonia, France, Germany, Ireland, The Netherlands and Sweden. For more information about the company, including Repligen news releases, see our website at www.repligen.com. Follow us on LinkedIn and Twitter.

Repligen Contact:
Sondra S. Newman
Global Head of Investor Relations
(781) 419-1881
investors@repligen.com